Page 1

燃 石 医学 Burning Rock Dx Burning Rock Reports Second Quarter 2021 Financial Results August 31 , 2021 GUANGZHOU , China , Aug. 31 , 2021 ( GLOBE NEWSWIRE ) -- Burning Rock Biotech Limited ( NASDAQ : BNR , the " Company " or " Burning Rock " ) , a company focused on the application of next generation sequencing ( NGS ) technology in the field of precision oncology , today reported financial results for the three months ended June 30 , 2021 . Business Updates • Early Detection • Technology foundation manuscript was published in Nature Biomedical Engineering ( article link here ) . The results demonstrate that our proprietary technology of deep methylation sequencing , aided by a machine - learning classifier of methylation patterns , enables ultrasensitive detection of circulating tumor DNA . • We continued to conduct an early - access program ( over 2,000 volunteers tested ) to prepare for operational readiness of our 6 - cancer early detection product . o 2022 commercialization is well on track . We are entering into contract signing stage with 6 hospitals where our 6 - cancer test will be offered at the health check - up departments of those hospitals . • New products for early - stage cancer patients • Development of minimal residual disease ( MRD ) products is on track . Products are targeted to be launched in 2022. Lung - cancer data read - out is likely to take place in the first half of 2022. Clinical trials on colon , esophageal and other cancers are also under planning . ⚫ Pharma Services . o Biopharma service contracts backlog grew rapidly . Total value of the contracts entered into during the first half of 2021 amounted to RMB98.2 million , three times the amount in full - year 2020 . • We are jointly developing , together with IMPACT Therapeutics , companion diagnostics ( CDx ) for a targeted oncology drug , Senaparib , ( IMP4297 ) , a PARP inhibitor , for the treatment of prostate cancer globally . Senaparib's pivotal clinical study under the FDA pathway is in progress . This project uses our Clinical Laboratory Improvement Amendments ( CLIA ) -certified and College of American Pathologists ( CAP ) -accredited laboratory in California , US . Therapy Selection o Continued to strategically focus on the in - hospital channel . The volume of in - hospital NGS - based test kits grew 70 % year - over - year to over 10,000 tests in the second quarter of 2021 . Second Quarter 2021 Financial Results Revenues were RMB127.3 million ( US $ 19.7 million ) for the three months ended June 30 , 2021 , representing a 19.0 % increase from RMB107.0 million for the same period in 2020 , or a 19.4 % sequential increase from RMB106.6 million for the three months ended March 31 , 2021 . • Revenue generated from central laboratory business was RMB80.0 million ( US $ 12.4 million ) for the three months ended June 30 , 2021 , representing a 7.2 % increase from RMB74.6 million for the same period in 2020 , primarily attributable to the year - over - year volume growth of the central laboratory business . Number of patients tested in the central laboratory channel was 8,155 for the three months ended June 30 , 2021 , representing a 12.5 % increase from 7,252 for the same period in 2020 . • Revenue generated from in - hospital business was RMB40.5 million ( US $ 6.3 million ) for the three months ended June 30 , 2021 , representing a 46.8 % increase from RMB27.6 million for the same period in 2020 , primarily attributable to the year - on - year volume growth of 70 % of the in - hospital business . Number of contracted partner hospitals in the in - hospital channel increased to 34 as of June 30 , 2021 from 32 as of March 31 , 2020 and 24 as of June 30 , 2020 . • Revenue generated from pharma research and development services was RMB6.8 million ( US $ 1.0 million ) for the three months ended June 30 , 2021 , representing a 41.9 % increase from RMB4.8 million for the same period in 2020 , primarily attributable to the building of pipeline of pharmaceutical projects . Cost of revenues was RMB37.0 million ( US $ 5.7 million ) for the three months ended June 30 , 2021 , representing a 29.7 % increase from RMB28.6 million for the same period in 2020 , which was generally in line with the Company's continued business growth . Gross profit was RMB90.2 million ( US $ 14.0 million ) for the three months ended June 30 , 2021 , representing a 15.1 % increase from RMB78.4 million for the same period in 2020. Gross margin was 70.9 % for the three months ended June 30 , 2021 , compared to 73.3 % for the same period in 2020 .